This title appears in the Scientific Report :
2019
Please use the identifier:
http://hdl.handle.net/2128/22182 in citations.
Please use the identifier: http://dx.doi.org/10.1038/s41598-019-41993-6 in citations.
Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
Alzheimer’s disease (AD) is a neurodegenerative disorder leading to dementia. Aggregation of the amyloid-β peptide (Aβ) plays an important role in the disease, with Aβ oligomers representing the most toxic species. Previously, we have developed the Aβ oligomer eliminating therapeutic compound RD2 co...
| Personal Name(s): | Elfgen, Anne |
|---|---|
| Hupert, Michelle / Bochinsky, Kevin / Tusche, Markus / González de San Román Martin, Estibaliz / Gering, Ian / Sacchi, Silvia / Pollegioni, Loredano / Huesgen, Pitter F. / Hartmann, Rudolf / Santiago-Schübel, Beatrix / Kutzsche, Janine (Corresponding author) / Willbold, Dieter (Corresponding author) | |
| Contributing Institute: |
Analytik; ZEA-3 Strukturbiochemie; ICS-6 |
| Published in: | Scientific reports, 9 (2019) 1, S. 5715 |
| Imprint: |
[London]
Macmillan Publishers Limited, part of Springer Nature
2019
|
| PubMed ID: |
30952881 |
| DOI: |
10.1038/s41598-019-41993-6 |
| Document Type: |
Journal Article |
| Research Program: |
Physical Basis of Diseases |
| Link: |
Get full text Get full text OpenAccess OpenAccess |
| Publikationsportal JuSER |
Please use the identifier: http://dx.doi.org/10.1038/s41598-019-41993-6 in citations.
| LEADER | 08025nam a2201165 a 4500 | ||
|---|---|---|---|
| 001 | 862746 | ||
| 005 | 20220930130211.0 | ||
| 024 | 7 | |a 10.1038/s41598-019-41993-6 |2 doi | |
| 024 | 7 | |a 2128/22182 |2 Handle | |
| 024 | 7 | |a pmid:30952881 |2 pmid | |
| 024 | 7 | |a WOS:000463482800054 |2 WOS | |
| 024 | 7 | |a altmetric:58931090 |2 altmetric | |
| 037 | |a FZJ-2019-02988 | ||
| 082 | |a 600 | ||
| 100 | 1 | |a Elfgen, Anne |0 P:(DE-Juel1)164354 |b 0 |u fzj | |
| 245 | |a Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers | ||
| 260 | |a [London] |c 2019 |b Macmillan Publishers Limited, part of Springer Nature | ||
| 520 | |a Alzheimer’s disease (AD) is a neurodegenerative disorder leading to dementia. Aggregation of the amyloid-β peptide (Aβ) plays an important role in the disease, with Aβ oligomers representing the most toxic species. Previously, we have developed the Aβ oligomer eliminating therapeutic compound RD2 consisting solely of D-enantiomeric amino acid residues. RD2 has been described to have an oral bioavailability of more than 75% and to improve cognition in transgenic Alzheimer’s disease mouse models after oral administration. In the present study, we further examined the stability of RD2 in simulated gastrointestinal fluids, blood plasma and liver microsomes. In addition, we have examined whether RD2 is a substrate for the human D-amino acid oxidase (hDAAO). Furthermore, metabolite profiles of RD2 incubated in human, rodent and non-rodent liver microsomes were compared across species to search for human-specific metabolites that might possibly constitute a threat when applying the compound in humans. RD2 was remarkably resistant against metabolization in all investigated media and not converted by hDAAO. Moreover, RD2 did not influence the activity of any of the tested enzymes. In conclusion, the high stability and the absence of relevant human-specific metabolites support RD2 to be safe for oral administration in humans. | ||
| 588 | |a Dataset connected to CrossRef | ||
| 700 | 1 | |a Hupert, Michelle |0 P:(DE-Juel1)142389 |b 1 |u fzj | |
| 700 | 1 | |a Bochinsky, Kevin |0 P:(DE-Juel1)165763 |b 2 |u fzj | |
| 700 | 1 | |a Tusche, Markus |0 P:(DE-Juel1)131709 |b 3 | |
| 700 | 1 | |a González de San Román Martin, Estibaliz |0 P:(DE-Juel1)168323 |b 4 | |
| 700 | 1 | |a Gering, Ian |0 P:(DE-Juel1)171922 |b 5 |u fzj | |
| 700 | 1 | |a Sacchi, Silvia |0 0000-0002-2338-2561 |b 6 | |
| 700 | 1 | |a Pollegioni, Loredano |0 0000-0003-1733-7243 |b 7 | |
| 700 | 1 | |a Huesgen, Pitter F. |0 P:(DE-Juel1)162356 |b 8 | |
| 700 | 1 | |a Hartmann, Rudolf |0 P:(DE-Juel1)132001 |b 9 | |
| 700 | 1 | |a Santiago-Schübel, Beatrix |0 P:(DE-Juel1)133853 |b 10 |u fzj | |
| 700 | 1 | |a Kutzsche, Janine |0 P:(DE-Juel1)159137 |b 11 |e Corresponding author |u fzj | |
| 700 | 1 | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 12 |e Corresponding author | |
| 773 | |a 10.1038/s41598-019-41993-6 |g Vol. 9, no. 1, p. 5715 |0 PERI:(DE-600)2615211-3 |n 1 |p 5715 |t Scientific reports |v 9 |y 2019 |x 2045-2322 | ||
| 856 | 4 | |u http://juser.fz-juelich.de/record/862746/files/16003723690008973348INVOIC2676139755001.pdf | |
| 856 | 4 | |u http://juser.fz-juelich.de/record/862746/files/16003723690008973348INVOIC2676139755001.pdf?subformat=pdfa |x pdfa | |
| 856 | 4 | |u http://juser.fz-juelich.de/record/862746/files/Metabolic%20resistance%20of%20the%20D-peptide%20RD2%20developed%20for%20direct%20elimination%20of%20amyloid-%CE%B2%20oligomers.pdf |y OpenAccess | |
| 856 | 4 | |u http://juser.fz-juelich.de/record/862746/files/Metabolic%20resistance%20of%20the%20D-peptide%20RD2%20developed%20for%20direct%20elimination%20of%20amyloid-%CE%B2%20oligomers.pdf?subformat=pdfa |x pdfa |y OpenAccess | |
| 909 | C | O | |o oai:juser.fz-juelich.de:862746 |p openaire |p open_access |p OpenAPC |p driver |p VDB |p openCost |p dnbdelivery |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)164354 | |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)142389 | |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)165763 | |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)131709 | |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)171922 | |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)162356 | |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)132001 | |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)133853 | |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)159137 | |
| 910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 12 |6 P:(DE-Juel1)132029 | |
| 913 | 1 | |a DE-HGF |b Key Technologies |l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-553 |2 G:(DE-HGF)POF3-500 |v Physical Basis of Diseases |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 | |
| 914 | 1 | |y 2019 | |
| 915 | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews | ||
| 915 | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record | ||
| 915 | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b SCI REP-UK : 2017 | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ | ||
| 915 | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index | ||
| 915 | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection | ||
| 915 | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID | ||
| 915 | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID | ||
| 915 | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central | ||
| 915 | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List | ||
| 980 | 1 | |a APC | |
| 980 | 1 | |a FullTexts | |
| 980 | |a journal | ||
| 980 | |a VDB | ||
| 980 | |a I:(DE-Juel1)ICS-6-20110106 | ||
| 980 | |a I:(DE-Juel1)ZEA-3-20090406 | ||
| 980 | |a APC | ||
| 980 | |a UNRESTRICTED | ||
| 536 | |a Physical Basis of Diseases |0 G:(DE-HGF)POF3-553 |c POF3-553 |f POF III |x 0 | ||
| 336 | |a ARTICLE |2 BibTeX | ||
| 336 | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1583736742_29854 |2 PUB:(DE-HGF) | ||
| 336 | |a Output Types/Journal article |2 DataCite | ||
| 336 | |a article |2 DRIVER | ||
| 336 | |a Nanopartikel unedler Metalle (Mg0, Al0, Gd0, Sm0) |0 0 |2 EndNote | ||
| 336 | |a JOURNAL_ARTICLE |2 ORCID | ||
| 981 | |a I:(DE-Juel1)IBI-7-20200312 | ||
| 920 | |l yes | ||
| 920 | |k Analytik; ZEA-3 |0 I:(DE-Juel1)ZEA-3-20090406 |l Analytik |x 1 | ||
| 920 | |k Strukturbiochemie; ICS-6 |0 I:(DE-Juel1)ICS-6-20110106 |l Strukturbiochemie |x 0 | ||
| 991 | |a Hartmann, Rudolf |0 P:(DE-Juel1)132001 |b 9 | ||
| 991 | |a Huesgen, Pitter |0 P:(DE-Juel1)162356 |b 8 | ||
| 991 | |a Pollegioni, Loredano |0 0000-0003-1733-7243 |b 7 | ||
| 991 | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 12 |e Corresponding author | ||
| 991 | |a Sacchi, Silvia |0 0000-0002-2338-2561 |b 6 | ||
| 990 | |a Elfgen, Anne |0 P:(DE-Juel1)164354 |b 0 |u fzj | ||
| 991 | |a Kutzsche, Janine |0 P:(DE-Juel1)159137 |b 11 |e Corresponding author |u fzj | ||
| 991 | |a Gering, Ian |0 P:(DE-Juel1)171922 |b 5 |u fzj | ||
| 991 | |a Santiago-Schübel, Beatrix |0 P:(DE-Juel1)133853 |b 10 |u fzj | ||
| 991 | |a González de San Román Martín, Estibaliz |0 P:(DE-Juel1)168323 |b 4 | ||
| 991 | |a Tusche, Markus |0 P:(DE-Juel1)131709 |b 3 | ||
| 991 | |a Bochinsky, Kevin |0 P:(DE-Juel1)165763 |b 2 |u fzj | ||
| 991 | |a Sydes, Michelle |0 P:(DE-Juel1)142389 |b 1 |u fzj | ||